New vaccine combo aims to boost cancer fight in lung and esophageal patients

NCT ID NCT04908111

Terminated Disease control Sponsor: Cancer Research UK Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests two experimental vaccines (ChAdOx1 and MVA) designed to help the immune system target cancer proteins MAGE-A3 and NY-ESO-1. About 15 adults with advanced non-small cell lung cancer or squamous esophageal cancer will receive the vaccines alongside their usual chemotherapy and an immune checkpoint inhibitor. The main goal is to check safety and tolerability, with a secondary focus on how long the disease stays under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Esophageal Neoplasms esophageal squamous cell carcinoma lung neoplasm neoplasm non-small cell lung carcinoma squamous cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC) SQUAMOUS OESOPHAGEAL CANCER

Contacts and locations

Locations

Beatson West of Scotland Cancer Centre

Glasgow, United Kingdom
Blackpool Victoria Hospital

Blackpool, United Kingdom
Churchill Hospital

Oxford, United Kingdom
Guy's and St Thomas' NHS Foundation Trust

London, United Kingdom
Leicester Royal Infirmary

Leicester, United Kingdom
Royal Preston Hospital

Preston, United Kingdom
Southampton General Hospital

Southampton, United Kingdom
St James's University Hospital

Leeds, United Kingdom
The Christie NHS Foundation Trust

Manchester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.